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Abstract
In an opinion published in 2012, we reviewed and discussed our studies of how
gene network-based guilt-by-association (GBA) is impacted by confounds
related to gene multifunctionality. We found such confounds account for a
significant part of the GBA signal, and as a result meaningfully evaluating and
applying computationally-guided GBA is more challenging than generally
appreciated. We proposed that effort currently spent on incrementally
improving algorithms would be better spent in identifying the features of data
that do yield novel functional insights. We also suggested that part of the
problem is the reliance by computational biologists on gold standard
annotations such as the Gene Ontology. In the year since, there has been
continued heavy activity in GBA-based research, including work that
contributes to our understanding of the issues we raised. Here we provide a
review of some of the most relevant recent work, or which point to new areas of
progress and challenges.
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Building better networks
One of the problems with network-based approaches we document-
ed in our previous papers1–3 is their tendency to converge on “easy 
answers”, by which we mean picking genes as candidates for a given 
disease or function simply because they are involved in many dis-
eases (multifunctional) or are prominent in the network (e.g., hubs)1. 
A possible solution would be to tailor the network data to particular 
contexts. Multifunctional genes would then have less of a dominant 
role, because fewer of their functions would be relevant to the net-
work, and the network might reflect this. Fortuitously, several studies 
that improve our understanding of the utility of context-specific net-
works recently appeared, though they do not address the questions 
of whether they reduce multifunctionality and node degree biases.
Guan et al. (2012) constructed 107 tissue-specific networks for the 
laboratory mouse to be used in disease-gene prioritization4. They 
used a combination of training data from Gene Ontology (GO) and 
tissue-specific expression signatures to customize their networks 
before moving to predicting disease candidate genes. The networks 
are not built from tissue-specific data, but various data used in com-
bination, with each given a weight computed using “tissue-specific 
gold standards”. The cross-validation performance improvement 
was significant but modest across most tasks (appearing to be ap-
proximately 0.03 on top of areas under receiver operating charac-
teristic curves (AUROCs) ranging from 0.7 to 0.8).
Magger et al. (2012) took a different approach, choosing to construct 
tissue-specific protein interaction networks by down-weighting edg-
es involving genes not expressed in the given tissue5. Their base-
line performances are somewhat higher than Guan et al. and also 
show improvement with tissue-specificity (from a mean AUROC of 
0.82 to ~0.88). However, the bulk of this performance improvement 
comes with simply removing genes not expressed in a given tissue. 
Magger et al. provide some evidence that edges involving such genes 
are the source of prediction errors, as simply down-ranking the genes 
after analyzing a generic (non-tissue-specific) network was not as ef-
fective. While Magger et al. primarily restricted themselves to exam-
ining disease-gene associations where the causal gene was judged to 
be tissue-specific, they did examine the full disease-gene data where 
gains from tissue-specificity were much more modest (approximately 
AUROC 0.83 to 0.845). In contrast to the specialized task, node re-
moval and attenuation of unexpressed genes performed particularly 
badly but only at low false positive rates (FPR). At high FPRs, node 
removal outperformed other methods, suggesting a trade-off be-
tween high precision and low precision prediction.
Piro et al. (2012) created co-expression networks from groups of 
genes expressed in specific mouse brain regions and used these 
together with other information to predict gene-disease relations 
from OMIM6. They report that integrating tissue-specific data sub-
stantially raises their candidate disease prioritization performance. 
However, the final performance does not appear to be better than re-
ported using quite old methods (~AUROC of 0.8 overall). Because 
they do not present results using a comparable “generic” network, 
it is difficult to tell if anything was gained.
Dowell et al. (2013) describe the creation and analysis of a mouse 
embryonic stem cell (mEPSC) specific gene network, relying on 
extensive manual curation7. This paper caught our attention in part 
because Dowell et al. acknowledge the potential for node degree 
bias and other issues, and claim “we address many of these poten-
tial pitfalls”. However, we were unable to identify the evidence that 
their methods do so; indeed, the focus on network hubs combined 
with very high performance of negative control data (assembled 
from datasets excluding mESCs), suggests multifunctional biases 
may have had a role. They suggest the use of cell-type-specific data 
should “reduce the impact of multi-functional genes”, but do not 
report whether this was indeed the case. This might have been of 
value in explaining how their network results were more specific, 
even if performance was not higher than some of the negative con-
trols overall. If context-specific data reduces generic effects, it is of 
utility even if it yields no improvements in performance as judged 
by the usual metrics.
These reports can be considered encouraging, but still leave open 
the question of whether parsing data into more specific subsets is 
worthwhile, despite the hopes we expressed last year on this count. 
The noisiness of biological data may be such that breaking data into 
smaller bins can cost more in terms of robustness than we gain in 
terms of specificity. We also note that some earlier approaches com-
bine a wide array of expression data, and treat the data sets as fea-
tures to be weighted in the prioritization method8,9. Thus information 
such as “gene A is expressed in tissue X” may have been implicitly 
used. Choosing “tissue-specific functions” to assess such approaches 
is another challenge, and it is unknown if multifunctionality effects 
are reduced. None of this eliminates the possibility that network 
specificity provides crucial value, but more data are required.
Using better controls
The GBA studies discussed in the previous section did not take the 
opportunity to test the effect of multifunctionality or node degree 
bias, despite this control being easy to perform. The clearest at-
tempt to control for multifunctionality and node degree of which 
we are aware is reported by Singh-Blom and colleagues in charac-
terizing their prediction tool, CATAPAULT. Singh-Blom et al. con-
ducted an analysis of disease and drug-target genes with a variety 
of networks and algorithms10. They report that a ranking of genes 
by multifunctionality (which they refer to as “degree”) performs 
poorly but not negligibly as a predictor, outperforming some of the 
methods they tested in cross-validation.
Before we comment further, there are some nuances to how 
Singh-Blom et al. (2013) use the multifunctionality ranking, com-
pared to how we did. First, to avoid confusion the multifunctional-
ity ranking (or a node degree ranking) should not be treated as a 
“method” for prediction, as it is referred to by Singh-Blom et al. 
It should be considered a null. In addition, the multifunctionality 
ranking is expected to “perform best” when performance is meas-
ured using ROC curves; Singh-Blom et al. use something more 
akin to precision-recall, which tends to obscure the influence of 
multifunctionality (and node degree), while being more heavily in-
fluenced by critical edges. Finally, multifunctionality ranking may 
be a too-stringent control (when using ROC) because it is literally 
optimized and performs better than many real algorithms on actual 
data1; rather, the correlation of the “real” prediction results with 
multifunctionality ranking is often a more helpful measure.
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In any case, the fact that the multifunctionality ranking yields even 
modest performance in the evaluation scheme of Singh-Blom et al. 
hints that this ranking is also correlated with network node degree 
(as explained in our work1), and furthermore that such effects will 
have a strong impact on their results. Accordingly, Singh-Blom 
et al. report that highly prioritized genes tend to have high network 
node degree. They also report that of the top 10 candidates for eight 
diseases, almost all were shared among two or more of the diseases, 
confirming our finding that GBA too often yields “generic” pre-
dictions, not function-specific ones. These results, using different 
algorithms, networks and evaluation metrics than us, provide strong 
independent support of our claims.
While Singh-Blom et al. confirmed some of our key findings, we 
may differ with them in interpretation, as they argue that the results 
are unproblematic. We agree with them that non-specific predic-
tions could be correct, but this does not absolve concern about how 
their methods are actually operating. For example, INSR (insulin 
receptor) was predicted by CATAPAULT as a leukemia candidate 
gene, in addition for other diseases (including other cancers and dia-
betes). We are led to suspect this is at least partly explained by the 
high node degree of INSR, and not specific “guilt by association” 
of INSR with known leukemia genes. Can one find literature that 
connects insulin receptors and leukemia? Of course, since both are 
highly studied (one can find papers linking insulin receptors or can-
cer to many things) and the metabolism of cancer cells is of interest 
from a therapeutic standpoint. We also note that TP53 was predicted 
to be a diabetes-related gene by CATAPAULT. It remains possible 
that INSR is a bona fide leukemia gene; regardless, we strongly 
believe that a biologist wanting to use the output of CATAPAULT 
would also want to know about the specificity of the predictions.
We hope that other researchers interested in why their methods work 
take the step of attempting to control for “generic” results. Other-
wise methodological performance is open to profound misinterpre-
tation as to true utility. This is true even in the case where authors 
are clearly aware of the potential for problems. For example, Zuberi 
et al. (2013) report that the GeneMANIA edge weight normaliza-
tion “helps to reduce the impact that the pleiotropy of high degree 
nodes has on functional predictions”9. We showed previously Gene-
MANIA’s results (with the normalization) are strongly affected by 
node degree, and indeed a substantial fraction of performance as 
measured by ROC curves could be explained by node degree ef-
fects1. Likewise, Verbeke et al. (2013) describe a gene prioritization 
method based on local networks that they “assume” reduces the ef-
fect of hubs, but provide no direct test11. As we have documented1, 
various attempts to modify networks to reduce extremes of node 
degree at best hide the problems from detection. We are open to the 
possibility that the approach of Verbeke et al. has the desired effect.
Finding better algorithms
In the last year, there have been several interesting evaluations of 
gene function prediction methods. Our interest lies less in which 
method does best than in what these evaluations expose about the 
state of the field as a whole.
Börnigen et al. (2012) performed a comparison of eight disease 
prioritization tools on a set of 42 disease genes12. The task was to 
prioritize the correct candidate, given whatever input the method 
requires (typically involving definition of a training set of genes 
already associated with the target function, and often a list of ~100 
candidates in a genomic interval as starting points rather than a 
genome-wide list). The results were evaluated with ROC curves and 
with true positive rates at a given threshold. The authors’ method, 
Endeavour13, was among the top evaluation performers. No evalua-
tion of the impact of multifunctionality was undertaken, but our ex-
perience suggests that multifunctional genes tend to be prioritized 
by these types of methods14. The problem of multifunctionality 
biasing prioritizations may be at least partly due to the difficulty of 
obtaining less biased training data. The “known genes” are often 
going to be biased towards highly-studied genes which do not form 
a sufficiently specific starting point for making functionally specific 
predictions. Regardless, Börnigen et al. were unable to clearly dis-
tinguish a best or poorest method, and the reasons for differences 
were not identified; it was speculated that differences in the under-
lying data used were important.
The more ambitious Critical Assessment of Functional Annotation 
(CAFA)15 was set up in a model very similar to the (now discontinued) 
function prediction component of CASP6 and CASP716,17. Participat-
ing groups predicted GO annotations for poorly-annotated proteins, 
followed by a waiting period during which some of the targets hap-
pened to be annotated by GO curators. The submitted algorithms were 
then assessed for correctness, relying primarily on a novel gene-centric 
metric that allowed partial credit for predicting a “similar” term, based 
on proximity in the GO term graph. Unfortunately, it emerged that this 
metric led to many methods (including BLAST) being outperformed 
by a naïve ranking of functions by prevalence (e.g., simply predict 
functions which are common overall; this approach ranks third or 
fourth in molecular function prediction), leading the organizers to ex-
clude some results15. Radivojac et al. (2013) concluded that simple se-
quence analysis methods such as BLAST perform poorly, while more 
sophisticated methods based on integrating diverse data types are a 
substantial boon. However, in our separate assessment of a substantial 
portion of the CAFA data, we found that by more conventional metrics 
BLAST was among the top performers18.
Our concerns about how function prediction works are further sup-
ported by a closer inspection of the methods that did well in CAFA. 
The best performing of them frequently have embedded in them 
aspects of the naive scoring method; that is, they successfully use 
knowledge of GO structure and term prevalence. In combination 
with the gene-centric evaluation metric, this creates a misleading 
impression of predictive power, in much the same way that a cold-
reading mentalist can exploit the prevalence of names and medi-
cal conditions to impress a gullible audience. It was also possible 
to benefit from existing annotations for the targets (hot reading18). 
While successful in the narrow confines of the assessment, if put to 
use such approaches would only serve to increase the already strong 
biases in GO. In other words, in a sense CAFA turned out to be less 
about predicting gene function than about predicting which proteins 
would be annotated by GO curators and with which terms.
One of the major issues faced by CAFA is how to operational-
ize “function”. They (understandably) pass the buck on this issue 
and take the GO as an appropriate way to define function, with a 
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number of consequent problems. In contrast, DREAM19 is a set of 
critical assessments motivated, like CAFA, as a means of under-
standing and improving inference methods (particularly network 
based ones), but DREAM largely focuses on more specific prob-
lems with associated datasets. One DREAM assessment we found 
interesting (even though it is not strictly about function prediction) 
focused on breast cancer survival analysis, with the goal of us-
ing molecular data (expression and genomic copy number) to im-
prove prediction beyond that provided by clinical features. While 
a number of performance comparisons were made, one result was 
that the baseline method - simple Cox regression on clinical fea-
tures – outperforms most methods across most conditions, even 
when they include the use of the molecular data. In only 10 out of 
28 submissions were models incorporating molecular feature data 
with clinical able to outperform the baseline clinical predictor. On 
the one hand, this is encouraging: molecular data may be able to 
contribute something. On the other hand, the very best method us-
ing clinical data only was very close in performance to the best 
performing method using combined data. As is typically the case 
in machine learning, ensemble methods performed well (this would 
also have been true in CAFA), although investigator-based choices 
also appear to have been critical, since the class of purely automated 
methods performed particularly badly. In addition, the control of 
incorporating random gene signatures (or generic/multifunctional 
ones) with clinical data appears not to have been attempted (as 
might be suggested by previous research20), with permuted case 
labelling serving as the negative control instead. This leaves open 
the possibility that to the extent molecular data is of any predictive 
value at all, it does not provide us with any guidance as to molecular 
mechanism (by singling out relevant subsets of genes).
The last assessment we consider is the Critical Assessment of Ge-
nome Interpretation (CAGI), which focuses on using sequence data 
to predict elements of clinical or molecular phenotypes. While the 
results have not been published formally, the data presented on the 
CAGI web site are informative (https://genomeinterpretation.org/). 
The issue of appropriate controls again rears its head. For example, 
in the 2011 “personal genome project” assessment of phenotype pre-
diction, the top performing submission appears to have primarily ob-
tained performance by predicting that rare phenotypes would not oc-
cur (“due to predicting absence of rare characteristics”). In another 
competition, ROC curves for predicting Crohn’s disease from exome 
data appear to show close to half of teams performing below random 
(although not significantly so, apparently due to low sample size).
Why are critical assessments done? An admirably thoughtful dis-
cussion of algorithm comparisons noted that most scientists read 
new papers thinking “well, of course they say their method is better, 
but…”21. In part, critical assessments were intended to solve this 
problem: to help us move forward by making truly representative 
comparisons. It is not clear this is what is happening for function 
prediction assessments. Instead, we now have a system where re-
searchers agree to participate and organizers have an obligation not 
to embarrass them. Thus, often only the top-performing methods 
are discussed, and the organizers have the same capacity to tweak 
as the original algorithm developers would have, and many of the 
same incentives. Discovering that most methods perform quite 
badly should be headline news, but could reduce enthusiasm for 
participation to the point of killing off future assessments. This is 
the usual problem of negative results, but scaled up to apply to the 
whole field through “consensus”. Perhaps publications of critical 
assessment should devote equal space to characterizing why meth-
ods failed; DREAM’s characterization of the poor performance of 
molecular data offers a toehold on this issue.
To summarize this section, because there are decreasing returns in 
tweaking methods, in our view comparisons of algorithms are less 
important than asking if they work at all and if so, how. Unfortu-
nately this is often very difficult to discern from most of the work 
that has emerged in the last year, which often vary data as well as 
algorithms, and do not provide enough information to judge poten-
tial drivers of performance such as multifunctionality effects.
Using prior knowledge
As we noted last year, gene function prediction shouldn’t simply 
reduce to information retrieval, at least not unwittingly. Organizing 
existing knowledge and finding overlaps is useful, but is not the 
principal motivation of network-based methods, which are intended 
to find novel features in rich data. One way of drawing a distinction 
is that information retrieval GBA does not as readily suggest novel 
experiments. Normally, using some experimental feature to draw a 
functional conclusion suggests that one should try perturbing that 
experimental feature and observing the result; this will seem re-
dundant if the feature is purely a property of the way the data was 
explicitly organized. However, the influence of prior knowledge is 
often hard to discern in the output of prediction methods, so infor-
mation retrieval can masquerade as de novo function prediction.
It is important to realize that methods motivated by information 
retrieval are still forms of GBA, and are subject to the same po-
tential problems. For example, Hoehndorf et al. (2013) created a 
network of genes based on semantic similarity of phenotypes of 
genetic diseases and animal models of diseases (PhenomeNet)22. 
They then use sets of genetic disease genes from various human 
databases, and their orthologs in mouse, to evaluate the relevance 
of this network for identifying gene-disease associations. For ex-
ample, they rank mouse genes by the similarity of their mutant phe-
notypes to a target human disease’s phenotypes. They claim their 
approach is not GBA because “it does not require prior knowledge 
of the genetic basis of diseases for its predictions”. This is incorrect: 
because their method uses associations (semantic similarity) and 
infers “guilt” (involvement of a gene in a disease) based on this, it is 
obviously GBA, albeit a simple one where the prediction algorithm 
is a simple ranking of nodes by similarity. The authors may have 
been hoping that they don’t need to worry about node degree effects 
and multifunctionality, but we disagree. Using semantic similarity 
to identify diseases that resemble mouse models seems reasonable; 
using this to predict disease genes is most definitely GBA and suf-
fers all the same potential pitfalls (and then some).
To see why, we note that the nodes in the network used by 
Hoehndorf et al. can be regarded as the set of both genes and diseases/
phenotypes with edges indicating high semantic similarity across 
phenotypes. A disease node then provides the training data (a set of 
associated genes), and nearby gene nodes are the predicted relevant 
genes. By taking the gene-centred data (mutants, etc.) and treating it 
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as equivalent to disease the authors are incorporating a hypothesis in 
addition to GBA, not instead of it. That is, a disease is treated con-
ceptually as if it was gene-like. Consider that the same model should 
work if we were trying to predict effects of mutations from other 
known mutation effects through cross-validation, which would then 
be GBA (but also including an information retrieval component).
The use of various flavors of annotation similarity to build or in-
fluence networks is already endemic in function prediction, as we 
noted previously. A recent example is the work of Youngs et al. 
(2013), who use information on GO annotations to compute priors 
for function prediction23. In this manner, the likelihood that a gene 
is predicted to be annotated with a certain GO term is influenced by 
whether its other annotated GO terms tend to co-occur with desired 
GO term. This method, which is influenced by early work24 per-
forms strongly in cross-validation, but we see two issues. The first 
is that, once again, the authors claim their evaluation approach ad-
dresses biases we have reported, without providing evidence. Sec-
ond, it treats annotation biases as something to exploit (somewhat 
like Singh-Blom et al.), which we regard as a shaky proposition 
when it comes to predicting gene function, as opposed to perform-
ing information retrieval.
One interesting feature of the attempts to improve networks, meth-
ods, and priors in GBA is that researchers in each area can take the 
other area to be a gold standard. Thus, researchers focusing on pro-
tein interaction networks may use GO to obtain “better” interaction 
data25. Conversely, researchers wish to treat the network as a gold 
standard to improve GO26,27. In the meantime, algorithm developers 
treat both networks and annotations as a gold standard when com-
paring methods. In all these cases, researchers are performing what 
we would call “GBA” and working with the alignment between 
how genes form groups (using some method) as characterized in 
data and how those genes are grouped by prior annotations. The 
fact that there is some form of alignment is repeatedly rediscovered. 
A problem we perceive is that the duality of the gold-standards is 
increasingly blurring the lines between predictions and data. For 
example, Dutkowski et al. (2013), when benchmarking their meth-
od against GO, initially used as input some networks that were in-
fluenced by data from GO (e.g., YeastNet25), and so had to perform 
separate experiments to remove this confound. Similarly, the work 
of Magger et al. discussed above used data on disease gene expres-
sion patterns28 that were derived in part from the same protein in-
teraction data that Magger et al. then use to perform tissue-specific 
predictions, though the implications of this are unclear. Recently 
we documented how protein interactions and gene ontology annota-
tions are in many cases derived from the same publications29. Data 
resources used in genomics are becoming more intertwined, so 
ever greater care is required to avoid contaminating computational 
experiments with unwanted biases.
GBA success stories?
Guilt by association is widely agreed to be a valid method for in-
vestigating gene function. As mentioned, our concerns largely have 
to do with how GBA is performed and evaluated computationally 
(though the biases in existing knowledge could have impact on 
GBA even when it is conducted by hand). We also want to know, 
when GBA does work, is it because of “generic features” such as 
node degree, or are the GBA methods working the way most com-
putational biologists hope they are working, which is inferring spe-
cific things about a gene based on specific features of its network 
neighbors. It is therefore of great interest to us and the rest of the 
computational GBA field to see use of GBA “in the wild”.
Our review of the literature reveals different stories for disease gene 
prioritization and for other function prediction tasks. It is uncom-
mon to see papers that report using computational GBA as an impor-
tant means of identifying genes with a desired function (ignoring the 
role of sequence similarity, which is no doubt the most-used GBA 
method; methods that use more complex network-based approaches 
are our focus here). In contrast, genetics researchers faced with a 
genomic interval or a set of candidates seem to more readily turn to 
prioritization tools for assistance. This may be because the task of 
prioritizing a few genes (often 10–20) is simpler than prioritizing the 
entire genome, or that the task of identifying a disease gene is more 
clearly defined.
To take a well-known method as example of how algorithms are 
used in practice, GeneMANIA is implemented in a web-based 
tool described by its developers as a gene recommender system – 
essentially, using GBA9. A survey of recent citations suggests that 
the function prediction aspect is not the focus of most users of 
GeneMANIA30–34; in some cases users express an interest in pre-
dicting interactions, but not functions35. This may be because Gene-
MANIA’s tools do not operate on functions as usually defined in 
GBA settings; they take as an input a set of genes chosen by the 
user, and show a gene network with nodes selected using the Gene-
MANIA algorithm. In this way it is very similar to STRING36 and 
HumanNet37, which generate gene networks, which are adjusted by 
their agreement with inputs such as GO. We suspect some users of 
GeneMANIA, STRING and HumanNet do not realize that they are 
looking at the output of a guilt-by-association-influenced approach.
This is not to say that computational methods are not directly used 
successfully for function prediction. But even in such cases, it is 
often very difficult to determine how exactly GBA worked. Users of 
GBA are justifiably relatively uninterested in how they get to an an-
swer, only that it is correct and leads to a new set of testable hypoth-
eses or insights. Thus GBA success stories tend to be somewhat 
light on details and heavy on ad hoc aspects. We briefly mentioned 
several success stories in our original commentary. Some additional 
examples have since come to light and bear discussion.
Tacutu et al. (2012) provide a valuable rare large-scale assessment 
of a computational GBA task38. They wished to predict genes in-
volved in regulating the longevity of Caenorhabditis elegans. Their 
input is a set of 205 known longevity-associated genes (LAGs) in 
a worm protein interaction network of 871 genes. A similar net-
work was constructed for human orthologs. They then made pre-
dictions in a simple way, considering any gene that was a network 
neighbor of known LAGs (or orthologs), limited to the subset of 
candidates that are required for development (essential genes). 
This yielded 500 candidates of which 374 were tested. They report 
19 of these validated, a success rate of 5%, compared to a rate of 
2.4% based only on genes critical for development. It is notable that 
most of the predictive information came from exploiting the prior 
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knowledge that essential genes were good candidates: the success 
rate went up five-fold from ~0.5% (for genome-wide screens) to 
2.4% for essential genes, whereas adding the protein interaction data 
increased success by another two-fold. Tacutu et al. do not report 
any information on potential node degree effects, but obviously the 
largest number of candidates would have to come from the highest 
node-degree LAGs given the simplicity of the method. We suspect 
that many GBA experts would want to know how it would have 
worked with “better data” and a “more sophisticated algorithm”.
Putnam et al. (2012) sought to identify yeast genes suppressing 
genomic instability39. Their initial input was 75 genes already 
known to be involved in genomic instability, and 928 genes in 
which mutations cause sensitivity to DNA damage. This set was 
expanded by choosing genes which have similar profiles of ge-
netic interactions – this appears to be their key GBA step. The 
final set of genes numbered 1041, which were further prioritized 
in a second GBA-like step, based on their genetic interaction pro-
files with known DNA damage response genes, and by apparently 
manual selection, leading to selection of 87 genes for experimental 
follow-up. Of these, 40% had a detectable effect on genomic stabil-
ity when mutated. This is impressive, but it is difficult to quantify 
the contribution of computation versus manual selection, and rela-
tively few candidates were entirely novel. The authors speculate that 
their success rates might have been even higher if they had genetic 
interaction from a more relevant phenotype. For example, many 
genes that clustered with known DNA damage-related genes – and 
which thus looked “guilty” - failed to validate. As in the case with 
Tacutu et al., we note the relatively simple data used and the simple 
approach, combined with hand-tuning.
We have also reviewed some recent applications of disease gene pri-
oritization tools, which as we comment above are seemingly used 
more commonly than function prediction tools (even though they 
are conceptually similar). We are struck by two trends. First, many 
(perhaps most) papers that apply such methods make no strong con-
clusion as to whether they have found the right gene40–48. That is, the 
results are treated a bit like GO enrichment analyses: as suggestive 
or exploratory. Second, some papers that report prioritization tool 
results supplant them with more precise or manually-identified in-
formation, such as the existence of an orthologous mouse mutant 
that has similar phenotypic features49–52.
We note a few trends from these reports. Black-box application of 
existing prioritization methods played at best a supporting role. 
The use of custom methods for creating initial target sets were im-
portant, sometimes based on experiments under the investigator’s 
control, rather than existing annotations from public databases. 
Data that was specific to the biology was deemed important: using 
generic data is a fallback. Not surprisingly, even with these ingre-
dients, success in converting computationally-prioritized genes into 
documented hits is far from guaranteed. And while these examples 
bolster the claim that GBA can work, exactly how they are working 
with regards to multifunctionality bias is still left unclear.
Conclusions
A theme that emerges from our review is brought out by the differ-
ence between the practices of computational biologists and those 
who actually use function prediction tools (loosely defined). These 
differences should come as no real surprise, but it has important im-
plications that we feel are not being attended to sufficiently. It may 
be that biologists are happy with high-quality information retrieval 
tools, and are not actually very interested in function prediction at 
all. That creates a difficulty for those who are interested in predict-
ing function, who feel compelled to develop new methods to do so, 
and who want their tools to be used by others. Such practitioners are 
left to test their methods on the GO, which we are increasingly cer-
tain is a waste of time, in the sense that it isn’t realistic, it isn’t what 
interests biologists, and it is easily confounded with the data used 
for prediction. It remains difficult to tell when methods are actually 
doing something useful, because evaluations have been weak, and 
the “in the wild” uses are obfuscated by various hand-tunings, pub-
lication bias, or inadvertent cherry-picking.
We regard these as major issues, but this is a far cry from disagree-
ing with functional inference overall. Some authors appear to have 
interpreted our papers as concluding that GBA is useless53,54, but 
this is too broad a brush. We fully believe in the GBA principle, and 
computational methods can be useful. The difficulty is in telling 
when and how they are working. The concern about “when” is sum-
marized by our findings that cross-validation analysis can be very 
misleading – to the point of being potentially irrelevant - for pre-
dicting future performance2. The concern about “how” is reflected 
in our demonstrations that gene multifunctionality and node degree 
effects are often more important in determining the outcome of a 
GBA analysis than details about the connections in the network1. 
These two realizations should affect practice, but they do not mean 
that the predictions one makes are always incorrect.
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The authors have discussed the pitfalls of automated GBA and ways to improve functional prediction.
Automated methods for GBA are only as good as ontologies and curated reference datasets. Ontologies
like GO suffer from poor quality annotation being propagated throughout their data that result in “Garbage
in – Garbage out” phenomenon. A generic functional prediction is the best one can expect from existing
automated methods.
From my experience, I have found that accurate functional prediction requires a mix of local sequence
similarity and sequence profile searches, proper sequence analysis with study of sequence and phyletic
conservation, structural analysis, network studies of various data points, and correlation with experimental
data, all done with a heavy dose of manual tuning. None of the automated methods of GBA give
consistent accurate prediction, without manual intervention.
The review laid out by the authors is a good analysis of the challenges and limitation of gene function
prediction. One area that the authors do not explicitly discuss is the great difference between eukaryotes
and prokaryotes. GBA is currently far more effective in the latter due to operons, which are not available in
eukaryotes.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
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This opinion article deals with the long standing issue of protein function prediction in its broader sense.
The authors express an interesting and most of the time shareable point of view about the negative
impact of gene multifunctionality that influences gene network-based guilt-by-association studies.
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The paper is really well written and organized in sections that focus on different aspects of function
prediction and its pitfalls. Nonetheless, there are some minor points that I would suggest mitigating, as
they sound too harsh and are, as far as I’m concerned, partly incorrect.
In the “ ” section, CAFA is mentioned and commented on but I would like toFinding better algorithms
pinpoint some aspects about how this is done and some related issues (below). Even the glorious series
of CASP experiments, that the authors have mentioned, suffered a lot in their first editions but what is
more important is that both assessors and participants are aware of this and that improvements are
planned, as far as I know.
The prediction results from the CAFA experiment could perhaps be framed around some different points
of view:
1:
Looking at the F-measure results for top performing methods there is little to be happy about. There are
the following additional issues coming out from CAFA: are we really sure that some of the predicted
functions are not correct? Is this rather an effect caused by the possible incompleteness of some
experimental data? In other words, can anyone assert firmly that there is nothing else to discover about
the function of a protein? I would definitively say NO. There is more than meets the eye and besides, the
benchmark is incomplete by definition as it will never complete in the future either, no matter what
information is added. Not only that, but even novel experimental evidence can turn false positive
predictions of protein function into a true positive. On the flip side, true positive predictions can equally be
refuted by fresh experimental data and consequently turn into a false positive.
 
2:
Some functions of the CAFA experiment were extremely difficult to predict and hard to “guess” in any
way, both from a simple sequence similarity approach or other more sophisticated techniques based on
machine learning. In summary, some CAFA targets were not so easy to predict.
 
3:
Additionally with CAFA, much marginally informative experimental data was collected for many targets
that mainly derived from PPI experiments. The term under indictment is “protein binding” which is heavily
present, for example, in the GOA database of annotated proteins. The assessors’ decision to discard
“protein binding” in the final evaluation was, consequently, correct. The good performance of naïve and
BLAST methods (when “protein binding” is considered in the assessment) depends on the high
occurrence (multifunctional?) of one function in the database and its prevalence over the others so that it
is very easy “to predict”. In this sense, it is not exactly correct to assert that BLAST and naïve are (almost)
the best performing tools because many tools participating to CAFA, whenever possible, tried to provide
more informative annotations in place of the less informative “protein binding”. Taking this into account,
“protein binding” would have been inappropriate to use in the final evaluation because it would have
rewarded BLAST and naïve methods artificially but penalized others.
In contrast, the main issue is that databases contain biased annotations and a few scarcely informative
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In contrast, the main issue is that databases contain biased annotations and a few scarcely informative
terms dominate the scene. In this respect, I totally agree with the authors that multifunctionality poses
serious problems to function prediction algorithms. So how might one mitigate the effect of multifunctional
and scarcely informative annotations? 
Perhaps CAFA will need to settle in the next editions and the contribution to this process of renewal
should be constructive and proactive rather than purely critical.
 
4:
The authors recognize that successful stories may be limited, simple and hand-tuned. Reverse
engineering results is demanding and I agree with the authors, but I would note that the excess in the
analysis, as suggested in the when/how methods perform section, could lead to an
overestimate/underestimate of the behavior of the tools and miss their general action. As a matter of fact,
biology is made of more exceptions than rules and tools are designed to follow only the rules. Can the
authors suggest some possible ways in which a tentative solution can be set up that could be discussed
and adopted in critical assessments of function prediction tools?
 
 
5:
To me, the distinction in this paper between between GO and protein annotations using GO are not clear
enough. I would, for instance, rephrase the following: 
“…. We also suggested that part of the problem is the reliance by computational biologists on gold
standard annotations such as the Gene Ontology ….”
To something like:
“…. We also suggested that part of the problem is the reliance by computational biologists on gold
standard annotations such as the Gene Ontology Annotation database (GOA) ….”
I know the authors know the difference between the two and for this reason I would recommend that they
clarify this aspect and do not confound what GO and its countless instances are (one of them is GOA).
As an obvious reminder, GO is an abstraction of the knowledge tentatively organized in a directed acyclic
graph and is a controlled vocabulary intended as the rosetta stone of different interpretations and
expressions of the same concepts. I strongly believe that GO is rigorous and we can trust it. On the
contrary, GOA contains GO instances used to describe proteins. Using the metaphor of programming
language, the GO term is the “object” and its use in GOA, or other databases containing GO annotated
proteins, is the “instance” of that “object”. This is an important difference because the “object” is abstract
and may be varied in a number of ways that can be right or wrong when thinking about protein annotation.
It is not the GO term definition per se in the dock but rather its utilization as a descriptor of protein function
stored in public databases. The authors already published a paper on GO based annotations and their
distribution in GOA over time. In other words, one can rely on the GO descriptions and their positions in
the graph (though GO is continuously revisited, it is rather stable) but must pay attention to the proteins
annotated with GO terms because they can be inappropriate and change over time, as already evaluated
by the authors in a previous work (indeed, GO annotations in GOA change frequently).
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It would be very interesting to know what the authors think about the latter phenomenon, i.e. the updating
of old annotations and their syncing with novel and more precise GO ontologies.
Most of the issues, fully and carefully described by the authors, may be due more to this aspect than
others. Generic annotations may have been used at the beginning of the story when GO was still
incomplete and with poor coverage of biological knowledge. Thinking about “Inferred from Electronic
Annotations” (IEA), these GO terms may have created the multifunctional phenomenon as they had time
to spread and have consequently become both pervasive and difficult to eradicate or update.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Page 12 of 12
F1000Research 2013, 2:230 Last updated: 28 NOV 2014
